aTYR Pharma Nasdaq/NYSE Compliance Notice
aTyr Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously been under a deficiency notice since December 2025 and was granted an extension until November 30, 2026, to meet the standard. As of this filing, the company has no outstanding deficiency notices from Nasdaq.
- Counterparty
- Nasdaq